Showing 1 - 7 results of 7 for search 'James B Rowe', query time: 0.02s Refine Results
  1. 1
    Multiple modes of impulsivity in Parkinson's disease.

    Multiple modes of impulsivity in Parkinson's disease. by Cristina Nombela, Timothy Rittman, Trevor W Robbins, James B Rowe

    Published 2014-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    A longitudinal study of motor, oculomotor and cognitive function in progressive supranuclear palsy.

    A longitudinal study of motor, oculomotor and cognitive function in progressive supranuclear palsy. by Boyd C P Ghosh, Roger H S Carpenter, James B Rowe

    Published 2013-01-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Frontotemporal lobar degeneration changes neuronal beta-frequency dynamics during the mismatch negativity response

    Frontotemporal lobar degeneration changes neuronal beta-frequency dynamics during the mismatch negativity response by Alistair Perry, Laura E. Hughes, Natalie E. Adams, Michelle Naessens, Niels A. Kloosterman, Matthew A. Rouse, Alexander G. Murley, Duncan Street, P. Simon Jones, James B. Rowe

    Published 2024-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    New Therapeutics in Alzheimer’s Disease Longitudinal Cohort study (NTAD): study protocol

    New Therapeutics in Alzheimer’s Disease Longitudinal Cohort study (NTAD): study protocol by James B Rowe, Vanessa Raymont, Yun-Ju Cheng, Anna C Nobre, Juliette Helene Lanskey, Ece Kocagoncu, Andrew J Quinn, Melek Karadag, Jemma Pitt, Stephen Lowe, Michael Perkinton, Krish D Singh, Mark Woolrich, Richard N Henson

    Published 2022-12-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Pharmacological and pupillary evidence for the noradrenergic contribution to reinforcement learning in Parkinson’s disease

    Pharmacological and pupillary evidence for the noradrenergic contribution to reinforcement learning in Parkinson’s disease by Claire O’Callaghan, Frank H. Hezemans, Naresh Subramaniam, Rong Ye, Kamen A. Tsvetanov, Alexander G. Murley, Negin Holland, Isabella F. Orlando, Ralf Regenthal, Roger A. Barker, Caroline H. Williams-Gray, Luca Passamonti, Trevor W. Robbins, James B. Rowe

    Published 2025-08-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Noradrenergic deficits contribute to apathy in Parkinson's disease through the precision of expected outcomes.

    Noradrenergic deficits contribute to apathy in Parkinson's disease through the precision of expected outcomes. by Frank H Hezemans, Noham Wolpe, Claire O'Callaghan, Rong Ye, Catarina Rua, P Simon Jones, Alexander G Murley, Negin Holland, Ralf Regenthal, Kamen A Tsvetanov, Roger A Barker, Caroline H Williams-Gray, Trevor W Robbins, Luca Passamonti, James B Rowe

    Published 2022-05-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Noradrenaline for progressive supranuclear palsy syndromes (NORAPS): a randomised, double-blind, placebo-controlled, crossover Phase IIb clinical trial evaluating the efficacy and safety of oral atomoxetine for treating cognitive and behavioural changes in people with progressive supranuclear palsy syndromes in the UK

    Noradrenaline for progressive supranuclear palsy syndromes (NORAPS): a randomised, double-blind, placebo-controlled, crossover Phase IIb clinical trial evaluating the efficacy and... by Robert Durcan, Christopher Kobylecki, Lee Shepstone, James B Rowe, Alistair Church, Duncan Street, Vicky Marshall, Charlotte Russell, Luca Passamonti, Juliet High, Christopher T Rodgers, Boyd C P Ghosh, Kelly Grant, Natalia Igosheva, Hugo Paula, Colin McAlister, Simon P Jones, Rong Ye, Chrystalina Antoniades

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: